Y-mAbs Faces Delay In Pediatric Neuroblastoma With Refuse-To-File Letter

 
• By Joseph Haas
FDASignBldg21Entrance_1200x675
An FDA refuse-to-file letter will delay review of Y-mAbs' omburtamab

More from Clinical Trials

More from R&D